Company Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

Equities

301096

CNE1000056N5

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Ratings for Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

HANGZHOU BIO-SINCERITY PHARMA-TECH CO.,LTD.

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
67.46 ^CNY	-5.12%		-2.03%	+3.63%

Apr. 22	Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
2023	Tranche Update on Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s Equity Buyback Plan announced on August 24, 2023.	CI

Hangzhou Bio-Sincerity Pharma-Tech Co Ltd is a China-based company mainly engaged in comprehensive pharmaceutical technology research and development (R&D). The services provided by the Company mainly include entrusted R&D of pharmaceutical technology and transformation of independent R&D technological achievements. The entrusted R&D business provides integrated pharmaceutical R&D services such as pharmaceutical research, clinical trial and registration application for major pharmaceutical enterprises and pharmaceutical R&D investment enterprises. The transformation business of independent R&D technological achievements is based on the independent project research and development of drug R&D platform, and actively promote the transformation of independent R&D technological achievements after obtaining phased R&D achievements.

Number of employees: 1,321

CNY in Million	2022	Weight	2023	Weight	Delta
Transformation of Independent Research and Development Technological Achievements 38.6 %	221	36.4 %	392	38.6 %	+77.66%
Preclinical Pharmaceutical Research 33.2 %	218	36.0 %	338	33.2 %	+54.81%
Clinical Services 19.0 %	80	13.2 %	193	19.0 %	+141.25%
CDMO 5.2 %	21	3.4 %	52	5.2 %	+152.35%
Equity Share 2.9 %	58	9.5 %	30	2.9 %	-48.74%
Others 1.2 %	10	1.6 %	12	1.2 %	+24.41%

CNY in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	607	100.0 %	1,017	100.0 %	+67.51%

Managers	Title	Age	Since
Jin Fang Lou CEO	Chief Executive Officer	56	15-07-31
Dong Bo Yan DFI	Director of Finance/CFO	33	23-01-31
Fu Miao Hu		43	-
Bo Fan Song		35	-
Fei Jia BRD	Director/Board Member	45	18-12-12
Hui Ye BRD	Director/Board Member	38	17-04-30
Yi Fan Liu BRD	Director/Board Member	39	15-09-30
Chun Neng Shao BRD	Director/Board Member	56	11-05-31
Yi Xu IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Hui Lin Li BRD	Director/Board Member	67	19-06-25
Yong Zhou Hu BRD	Director/Board Member	74	19-06-25
Jin Fang Lou CEO	Chief Executive Officer	56	15-07-31
Chun Neng Shao BRD	Director/Board Member	56	11-05-31
Yi Fan Liu BRD	Director/Board Member	39	15-09-30
Cheng Ren BRD	Director/Board Member	48	20-06-19
Bo Fan Song CHM	Chairman	35	14-12-31
Fu Miao Hu CHM	Chairman	43	16-03-31
Hui Ye BRD	Director/Board Member	38	17-04-30
Ning Fan BRD	Director/Board Member	30	22-01-19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	108,919,903	54,969,803 ( 50.47 %)	777,300 ( 0.7136 %)	50.47 %

Name	Equities	%	Valuation
Hangzhou Qinghai Management Consulting Partnership LP 5.338 %	3,700,000	5.338 %	38 M ¥
Rongtong Fund Management Co., Ltd. 5.118 %	3,547,583	5.118 %	37 M ¥
Essence Fund Co., Ltd. 4.411 %	3,057,394	4.411 %	32 M ¥
Wei Jun Wang 3.895 %	2,700,000	3.895 %	28 M ¥
Zhuji Maicheng Pharmaceutical Technology LP 3.433 %	2,380,000	3.433 %	25 M ¥
Zhejiang Nongyin Fenghuang Investment Management Co. Ltd. 2.799 %	1,940,100	2.799 %	20 M ¥
Hangzhou Yirui Equity Investment Management Partnership LP 2.597 %	1,800,000	2.597 %	19 M ¥
Zhuji Lingjing Enterprise Management Partnership LP 2.380 %	1,650,000	2.380 %	17 M ¥
Zhuji Shengyang Enterprise Management Partnership LP 2.164 %	1,500,000	2.164 %	15 M ¥
China Universal Asset Management Co., Ltd. 2.072 %	1,436,600	2.072 %	15 M ¥

Name	Equities	%	Valuation
Chun Neng Shao 24.70 %	20,250,000	24.70 %	209 M ¥
Jin Fang Lou 20.49 %	16,800,000	20.49 %	173 M ¥

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd.

159 Oasis Road Donghu Street

311103, Hangzhou

http://www.hzbio-s.com

address Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.(301096)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

67.46

Average target price

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
HANGZHOU BIO-SINCERITY PHARMA-TECH CO.,LTD.	+3.63%	1.01B
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research